Cargando…

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer

BACKGROUND: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical...

Descripción completa

Detalles Bibliográficos
Autores principales: Arshad, Osama Ali, Datta, Aniruddha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374594/
https://www.ncbi.nlm.nih.gov/pubmed/28361666
http://dx.doi.org/10.1186/s12859-017-1522-2
_version_ 1782518921045213184
author Arshad, Osama Ali
Datta, Aniruddha
author_facet Arshad, Osama Ali
Datta, Aniruddha
author_sort Arshad, Osama Ali
collection PubMed
description BACKGROUND: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical castration. CRPC is a complex, multifaceted and heterogeneous malady with limited standard treatment options. RESULTS: The growth and progression of prostate cancer is a complicated process that involves multiple pathways. The signaling network comprising the integral constituents of the signature pathways involved in the development and progression of prostate cancer is modeled as a combinatorial circuit. The failures in the gene regulatory network that lead to cancer are abstracted as faults in the equivalent circuit and the Boolean circuit model is then used to design therapies tailored to counteract the effect of each molecular abnormality and to propose potentially efficacious combinatorial therapy regimens. Furthermore, stochastic computational modeling is utilized to identify potentially vulnerable components in the network that may serve as viable candidates for drug development. CONCLUSION: The results presented herein can aid in the design of scientifically well-grounded targeted therapies that can be employed for the treatment of prostate cancer patients.
format Online
Article
Text
id pubmed-5374594
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53745942017-03-31 Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer Arshad, Osama Ali Datta, Aniruddha BMC Bioinformatics Research BACKGROUND: Prostate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical castration. CRPC is a complex, multifaceted and heterogeneous malady with limited standard treatment options. RESULTS: The growth and progression of prostate cancer is a complicated process that involves multiple pathways. The signaling network comprising the integral constituents of the signature pathways involved in the development and progression of prostate cancer is modeled as a combinatorial circuit. The failures in the gene regulatory network that lead to cancer are abstracted as faults in the equivalent circuit and the Boolean circuit model is then used to design therapies tailored to counteract the effect of each molecular abnormality and to propose potentially efficacious combinatorial therapy regimens. Furthermore, stochastic computational modeling is utilized to identify potentially vulnerable components in the network that may serve as viable candidates for drug development. CONCLUSION: The results presented herein can aid in the design of scientifically well-grounded targeted therapies that can be employed for the treatment of prostate cancer patients. BioMed Central 2017-03-22 /pmc/articles/PMC5374594/ /pubmed/28361666 http://dx.doi.org/10.1186/s12859-017-1522-2 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Arshad, Osama Ali
Datta, Aniruddha
Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
title Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
title_full Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
title_fullStr Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
title_full_unstemmed Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
title_short Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
title_sort towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374594/
https://www.ncbi.nlm.nih.gov/pubmed/28361666
http://dx.doi.org/10.1186/s12859-017-1522-2
work_keys_str_mv AT arshadosamaali towardstargetedcombinatorialtherapydesignforthetreatmentofcastrationresistantprostatecancer
AT dattaaniruddha towardstargetedcombinatorialtherapydesignforthetreatmentofcastrationresistantprostatecancer